hydroxychloroquine has been researched along with Intestinal Obstruction in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Intestinal Obstruction: Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial." | 2.84 | Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. ( Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zeller, L | 1 |
| Barski, L | 1 |
| Shleyfer, E | 1 |
| Netz, U | 1 |
| Stavi, V | 1 |
| Abu-Shakra, M | 1 |
| Quach, LT | 1 |
| Chang, BH | 1 |
| Brophy, MT | 1 |
| Soe Thwin, S | 1 |
| Hannagan, K | 1 |
| O'Dell, JR | 1 |
| McAfee, Q | 1 |
| Zhang, Z | 1 |
| Samanta, A | 1 |
| Levi, SM | 1 |
| Ma, XH | 1 |
| Piao, S | 1 |
| Lynch, JP | 1 |
| Uehara, T | 1 |
| Sepulveda, AR | 1 |
| Davis, LE | 1 |
| Winkler, JD | 1 |
| Amaravadi, RK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy[NCT00405275] | 353 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Average difference between 48-week and Baseline DAS28.~The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure.~Low disease activity is defined as DAS28 ≤ 3.2 units." (NCT00405275)
Timeframe: 48 weeks after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Triple | -2.12 |
| Etanercept | -2.29 |
1 trial available for hydroxychloroquine and Intestinal Obstruction
| Article | Year |
|---|---|
Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Topics: Abscess; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etaner | 2017 |
2 other studies available for hydroxychloroquine and Intestinal Obstruction
| Article | Year |
|---|---|
Taenia solium in a patient with systemic lupus erythematosus: do parasites protect against autoimmune diseases.
Topics: Adult; Animals; Antibodies, Antinuclear; Antirheumatic Agents; Autoimmunity; Confusion; Digestive Sy | 2015 |
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antimalarials; Antineoplastic Agents; Autophagy; Autophagy | 2012 |